Studies table
An independent guide to peptides, SARMs and substances sold for longer life
Sorted alphabetically. Order does not imply a recommendation.
| Substances | Muscle mass | Strength | Recovery and injury | Longer life | Fat loss |
|---|---|---|---|---|---|
| 5-amino-1MQ | – | – | – | – | D |
| AOD-9604 | – | – | – | – | D |
| BPC-157 | – | – | D | – | – |
| Cagrilintide | – | – | – | – | B |
| Cardarine | – | – | – | – | C |
| CJC-1295 | C | – | – | – | – |
| Epitalon | – | – | – | D | – |
| GHK-Cu | – | – | C | – | – |
| GHRP-2 | D | – | – | – | – |
| hCG | – | – | – | – | A |
| IGF-1 LR3 | E | – | – | – | – |
| Ipamorelin | E | – | – | – | – |
| L-carnitine | – | – | – | – | C |
| LGD-4033 | B | – | – | – | – |
| MK-677 | B | C | – | – | – |
| MOTS-c | – | – | – | D | – |
| NAD+ | – | – | – | E | – |
| NMN | – | – | – | C | – |
| Ostarine | B | C | – | – | – |
| Oxytocin | C | – | – | – | B |
| Peptide blends | – | – | D | – | – |
| RAD-140 | D | D | – | – | – |
| Rapamycin | C | B | – | C | – |
| Retatrutide | – | – | – | – | A |
| Semaglutide | – | – | – | – | A |
| Sermorelin | D | – | – | – | – |
| Somatropin | A | A | – | – | – |
| SS-31 | – | C | – | – | – |
| TB-500 | – | – | D | – | – |
| Tesamorelin | – | – | – | – | B |
| Tirzepatide | – | – | – | – | A |
↑ Effect in studies↕ Conflicting results→ No effect in studies↓ Harm in studies? Not clearA grade says how strong the studies are, not whether a substance works.
Recent changes
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make BPC-157 on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make epitalon on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make KPV on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make MOTS-c on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make semax on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.